Patient-reported Outcomes in the Treatment of Schizophrenia

This study has been completed.
Information provided by:
Solvay Pharmaceuticals Identifier:
First received: September 12, 2005
Last updated: September 11, 2013
Last verified: September 2007

Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols

Condition Intervention Phase
Drug: bifeprunox
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials

Resource links provided by NLM:

Further study details as provided by Solvay Pharmaceuticals:

Study Start Date: May 2005
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participate in S1543003 and S1543004 in the U.S. sites

Exclusion Criteria:

  • Participate in S1543003 and S1543004 other than U.S. sites
  Contacts and Locations
Please refer to this study by its identifier: NCT00230828

Sponsors and Collaborators
Solvay Pharmaceuticals
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
  More Information

No publications provided Identifier: NCT00230828     History of Changes
Other Study ID Numbers: S154.3.005
Study First Received: September 12, 2005
Last Updated: September 11, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Schizophrenia and Disorders with Psychotic Features
Mental Disorders processed this record on April 23, 2014